Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.
Despite current guidelines recommendations about anticoagulant prophylaxis, many studies have shown an high venous thromboembolism (VTE) incidence in patients undergoing total hip and knee arthroplasty. A number of anticoagulants are currently available, but they have some limitations that affect their applicability and consequently their effectiveness. Several new oral anticoagulants (NOACs) have been developed in an attempt to overcome these limitations. Apixaban is a NOAC that selectively inhibits the coagulation factor Xa; it is approved for the prevention of VTE after total hip replacement and total knee replacement surgery. This review examines the results of main trials designed to test efficacy and safety of apixaban in major elective orthopedic surgery.
['Maniscalco|Pietro|P|', 'Caforio|Marco|M|', 'Imberti|Davide|D|', 'Porcellini|Giuseppe|G|', 'Benedetti|Raffaella|R|']
D000284:Administration, Oral D019644:Arthroplasty, Replacement, Hip D017984:Enoxaparin D065427:Factor Xa Inhibitors D006801:Humans D011720:Pyrazoles D011728:Pyridones D054556:Venous Thromboembolism
apixaban major orthopedic surgery review venous thromboembolism hip replacement knee replacement phase 3 clinical trials